Crystal Structure of Human Kynurenine Aminotransferase I*

The kynurenine pathway has long been regarded as a valuable target for the treatment of several neurological disorders accompanied by unbalanced levels of metabolites along the catabolic cascade, kynurenic acid among them. The irreversible transamination of kynurenine is the sole source of kynurenic acid, and it is catalyzed by different isoforms of the 5′-pyridoxal phosphate-dependent kynurenine aminotransferase (KAT). The KAT-I isozyme has also been reported to possess β-lyase activity toward several sulfur- and selenium-conjugated molecules, leading to the proposal of a role of the enzyme in carcinogenesis associated with environmental pollutants. We solved the structure of human KAT-I in its 5′-pyridoxal phosphate and pyridoxamine phosphate forms and in complex with the competing substrate l-Phe. The enzyme active site revealed a striking crown of aromatic residues decorating the ligand binding pocket, which we propose as a major molecular determinant for substrate recognition. Ligand-induced conformational changes affecting Tyr101 and the Trp18-bearing α-helix H1 appear to play a central role in catalysis. Our data reveal a key structural role of Glu27, providing a molecular basis for the reported loss of enzymatic activity displayed by the equivalent Glu → Gly mutation in KAT-I of spontaneously hypertensive rats.

In mammals, the kynurenine pathway is the main route for the degradation of tryptophan exceeding anabolic needs and represents the source for de novo NAD biosynthesis. Several metabolites along this pathway, collectively indicated as kynurenines, act as potent neuroactive compounds (1) exerting their function by either inducing free radicals generation (2) or engaging ionotropic excitatory amino acids receptors in the central nervous system (3). The amino acid L-kynurenine (L-Kyn) 1 is a key metabolite along this pathway, standing at the central branching point of the metabolic cascade (4). Indeed, L-Kyn undergoes different fates: i) it can be transformed to either 3-hydroxy-DL-kynurenine or anthranilic acid and conveyed into the flux of freshly synthesized NAD, or ii) it can be used for the synthesis of kynurenic acid (KA). A major role in the central nervous system is ascribed to KA. In fact, it represents the only known endogenous antagonist of the excitatory action of excitatory amino acids, showing the highest affinities for the glycine modulatory site of the Nmethyl-D-aspartate subtype of glutamate receptor (5-7) and the ␣7-nicotinic acetylcholine receptor (8 -10). Its inhibitory action underlies its neuroprotective and neurolectic properties; indeed, low endogenous brain KA level profoundly influences vulnerability to excitotoxic attacks (11)(12)(13)(14). On the other hand, a KA increase significantly correlates with schizophrenia (15) and cognitive impairment (16 -18) suggesting an additional role of KA in the pathophysiology of psychiatric disorders and mental retardation.
The KA requirement in the central nervous system is satisfied by the in situ irreversible transamination of L-kynurenine, catalyzed by kynurenine aminotransferases (KATs) (Fig. 1). The catalyzed reaction proceeds first through the transaldimination between the L-Kyn ␣-amino group and the pyridoxal 5Ј-phosphate (PLP) cofactor following the classical mechanism reported for aminotransferases (19); however, the subsequent catalytic events leading to the kynurenic acid formation are far from fully elucidated. KATs belong to the ␣-family of PLP-dependent enzymes and are considered members of aminotransferases fold type I subfamily (20). So far two KAT isozymes, termed KAT-I and KAT-II, have been identified in rat (21)(22)(23) and human (24) brains and have been extensively characterized. Both isozymes are capable of catalyzing the transamination of L-Kyn and to a lesser extent 3-hydroxy-kynurenine to kynurenic acid and xanthurenic acid, respectively, using many different ␣-ketoacids as amino group acceptors (25,26). KAT-I, also known as glutamine transaminase K, (27,28) is strongly inhibited by the competing substrates glutamine, tryptophan, and phenylalanine (26). Of functional relevance, KAT-I also displays cysteine conjugate ␤-lyase activity (29) and has been shown to activate sulfur-and selenium-conjugated compounds (30,31). This observation indicates an additional important role for KAT-I in the bio-activation of environmental pollutants contributing to liver-and kidney-associated carcinogenesis (28). Although the kidney and the liver show much greater KAT activity than the brain, the emphasis of KAT research has been placed on the enzymes in the central nervous system, paralleling the investigation of the pivotal role of KA therein.
We report here the crystal structure of human KAT-I (hKAT-I) at a resolution of 2.0 Å in its PLP and PMP forms as well as in complex with the competing substrate phenylalanine. Our results represent the first crystal structure of a human KAT to be reported, thus shedding more light into the * This work was supported by Grant AI 44399 from the National Institutes of Health and Ministero dell'Istruzione, dell'Università e della Ricera project FIRB2001. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The catalytic mechanism and substrate specificity. The determination of the three-dimensional structure of hKAT-I may contribute to the rational design of selective inhibitors of high medical interest in a number of pathological conditions in humans.

Enzyme Expression and Purification
Construction of Recombinant Transfer Vector for hKAT-I-The open reading frame for hKAT-I (NP_872603) was amplified from human liver cDNA (Clontech) using a specific forward (5Ј-CTCGAGATGGCCAAA-CAGCTGCAG, XhoI site underlined) and reverse (5Ј-AAGCTTAGAGT-TCCACCTTCCACTT, Hind III site underlined) primers pair. The PCR product was inserted into a TOPO TA cloning vector and then subcloned into the baculovirus transfer vector pBlueBac4.5 (Invitrogen). The recombinant transfer vector (pBlueBac-HsKAT I) was sequenced for frame verification of the inserted DNA sequence.
Production of Recombinant Baculoviruses for the Expression of hKAT-I in Insect Cells-pBlueBac-HsKAT I was co-transfected with linearized Bac-N-Blue TM viral DNA (AcMNPV, Autographa californica multiple nuclear polyhedrosis virus), in the presence of InsectinPlus TM insect cell-specific liposomes, to Spodoptera frugiperda (Sf9) insect cells (Invitrogen). The recombinant baculovirus was purified by plaque assay procedure. Blue putative recombinant plaques were transferred to 12well microtitre plates and amplified in Sf9 cells. Viral DNA was isolated for PCR analysis to determine the purity of recombinant viruses. High titer viral stocks for individual recombinant viral strains were generated by amplification in Sf9 cell suspension cultures according to the manufacturer's instructions.
hKAT-I Expression and Purification-Sf9 cells were cultured at 27°C in an Ultimate Insect TM serum-free medium (Invitrogen) supplemented with 10 units of heparin/ml (Sigma) in culture spinner flasks with constant stirring at 80 rev/min. When the cell density reached 2 ϫ 10 6 cells/ml, they were inoculated with the high titer viral stocks of the hKAT-I expressing recombinant baculoviruses at a multiplicity of infection of six viral particles per cell.
At day 4 after hKAT-I recombinant baculovirus inoculation, Sf9infected cells from a 2-liter culture were harvested by centrifugation (800 ϫ g for 15 min at 4°C). The pellet was dissolved in a lysis buffer containing 25 mM phosphate buffer, 150 mM NaCl, 0.1 mM PLP, 2 mM dithiothreitol, 2 mM EDTA, and 1 mM phenylmethylsulfonyl fluoride with a final pH of 7.4. After a 30-min incubation on ice, cell lysate was centrifuged at 18,000 ϫ g for 20 min at 4°C, and the supernatant was collected and assayed for KAT-I activity. Soluble proteins in supernatant were precipitated with 65% saturated ammonium sulfate. Protein precipitate was re-dissolved in 10% saturated ammonium sulfate and applied to a phenyl-Sepharose column. A linear gradient from 10 -0% of ammonium sulfate in 10 mM sodium phosphate buffer (pH 7.0) was used for protein elution. The hKAT-I active fractions were pooled, dialyzed, and separated by DEAE-Sepharose chromatography applying a linear NaCl gradient (0 -500 mM) in the same phosphate buffer. The active fractions were pooled again, concentrated, and then separated by a Superdex TM 200 gel filtration column. The hKAT-I active fractions were finally collected and concentrated. The purified protein content was determined by a Bio-Rad protein assay kit using bovine serum albumin as the standard. The purity of the enzyme was assessed by SDS-PAGE analysis. The concentration of the purified hKAT-I stock was adjusted to 20 mg/ml in 20 mM phosphate buffer (pH 7.5), aliquoted, and frozen at Ϫ80°C.

Crystallization, Data Collection, and Structure Determination
Crystallization-Crystals of the PLP form of human hKAT-I have been obtained using the vapor diffusion technique in hanging drop. 2 l of a protein solution at a concentration of 20 mg/ml were mixed with an equal volume of a reservoir solution containing 4.5 M ammonium formate, 0.1 M Tris (pH 7.5) and equilibrated against 500 l of a reservoir solution at 4°C. Yellow crystals grew to a maximum dimension of 0.3 ϫ 0.5 ϫ 0.7 mm in about 2 weeks. In the effort to obtain the complex with L-kynurenine, crystals of the PLP form of hKAT-I were soaked overnight at 4°C in their crystallization solution containing 3 mM L-kynurenine. A few minutes after soaking, the crystals became colorless, indicating the formation of the PMP form for which the structure is reported in the present study. The crystals of the hKAT-I⅐Phe complex were obtained by soaking crystals of the PLP form in their crystallization solution with the addition of 2.5 mM phenylalanine at 4°C overnight.
Data Collection-All data collections were performed at 100 K. Crystals were directly taken from the crystallization droplet and flash frozen under a liquid nitrogen stream. Diffraction data for the PLP form were collected up to 2.0 Å resolution using synchrotron radiation at the ID14 EH1 beam line, European Synchrotron Radiation Facility, Grenoble, France. Systematic absences and diffraction symmetry suggested a trigonal P3 2 21 or P3 1 21 space group with the following cell parameters a ϭ b ϭ 146.4 Å and c ϭ 67.5 Å containing one molecule in the asymmetric unit with a corresponding solvent content of 72%. X-ray diffraction data sets for the PMP form of the enzyme and for the hKAT-I⅐Phe complex were collected up to 2.9 Å and 2.7 Å resolution respectively, using in house equipment (RIGAKU RU300 rotating anode and RAXIS IVϩ area detector). Data processing was performed with the programs of the CCP4 suite (32). Statistics for data collections are listed in Table I.
Structure Determination-The structure determination of the PLP form was carried out by means of the molecular replacement technique, using as the search model the structure of Thermus thermophilus aspartate aminotransferase, (34% sequence identity; Protein Data Bank code 1GCK) (33). The program AmoRe (34) was employed to calculate both cross-rotation and translation functions in the 10 -4 Å resolution range. The rotation function gave a clear solution, which was subject to the translation function calculation performed in both the P3 2 21 and P3 1 21 space groups. Only for the former was a clear solution identified, unambiguously allowing us to assign P3 2 21 as the correct space group. The initial model was subjected to iterative cycles of crystallographic refinement with the program REFMAC (35) alternated with graphic sessions for model building using the program O (36). A random sample containing 834 reflections was set apart for the calculation of the free R-factor (37). Solvent molecules were manually added at positions with density Ͼ4 sigma in the F o Ϫ F c map, considering only peaks engaged in at least one hydrogen bond with a protein atom or a solvent atom. The procedure converged to an R-factor and free R-factor of 0.192 and 0.227, respectively, with ideal geometry.
The structures of the PMP form and of the hKAT-I⅐Phe complex were refined using (as the starting model) the final coordinates of the PLP form of the enzyme from which all solvent molecules were removed. In both cases the crystallographic refinement was carried out by means of the program REFMAC alternated with sessions of model building. 564 and 722 randomly chosen reflections were excluded from the refinement of the PMP and hKAT-I⅐Phe structures, respectively, and were used for the free R-factor calculation. For the PMP structure, a careful inspection of the electron density in the enzyme active site has been performed when the R-factor dropped to a value of 0.25 at 2.9 Å. No electron density compatible with either the substrate L-Kyn or the product KA was observed, and the enzyme was unambiguously identified as being in the PMP form. In the case of the hKAT-I⅐Phe structure, the ligand was manually modeled based on both the 2F o Ϫ F c and F o Ϫ F c electron density maps only when the R-factor dropped to a value of 0.26 at 2.7 Å resolution. For both the PMP and hKAT-I⅐Phe structures, solvent molecules were manually added following the same criteria adopted for the PLP form. The crystallographic refinement converged to an R-factor and an R-free of 0.17 and 0.22 for the PMP form, and an R-factor and R-free of 0.175 and 0.23 for the hKAT⅐Phe complex. In all the three structures the residues 1-3 and 149 -151 were not visible in the electron density map. Residues numbered 1*-422* refer to the crystallographically related subunit building the hKAT-I functional homodimer. The results of refinement are summarized in Table I.
Deposition-The atomic coordinates of hKAT-I in the PLP and PMP forms and in complex with phenylalanine, have been deposited with the Protein Data Bank (www.rcsb.org) (accession codes 1W7L, 1W7N, and 1W7M, respectively).

RESULTS AND DISCUSSION
Overall Quality of the Model-The three-dimensional structure of the recombinant human kynurenine aminotransferase I has been solved by means of the molecular replacement technique at a resolution of 2.0 Å. A monomer is present in the asymmetric unit and the functional homodimer could be observed in the crystal lattice, resulting from the application of the crystallographic 2-fold axis. An excellent electron density map allowed the modeling of 415 residues of 422, one PLP, and 305 solvent molecules in the PLP form. The final model of the PMP form contains 415 residues, one PMP, and 197 solvent molecules, whereas the hKAT-I⅐Phe complex consists of 415 residues, one PLP molecule, one L-Phe molecule, and 202 solvents. The stereochemistry of the models has been assessed with the program PROCHECK (38). In the case of the PLP form, 90% of the residues were in the most favored regions of the Ramachandran plot. Pro 123 , Pro 183 , and Pro 186 were all recognized as cis residues. Although Phe 278 falls in a disallowed region of the Ramachandran plot in all three structures solved, the excellent electron density allowed us to unambiguously assign the observed conformation. All the figures have been generated with the programs MOLSCRIPT (39) and BOB-SCRIPT (40).
Overall Structure-The hKAT-I protein architecture reveals the prototypical fold of aminotransferases subgroup I (19,41), characterized by an N-terminal arm, a small domain, and a large domain (Fig. 2). The N-terminal arm consists of a random coiled stretch made of residues 4 -17. The small domain (residues 18 -43 and 302-421) folds in a 5-stranded mainly antiparallel ␤-sheet surrounded by five ␣-helices. The large domain (residues 44 -301) shows a conserved ␣/␤ topology, where a sharply twisted 7-stranded ␤-sheet inner core is nested into a conserved array of eight ␣-helices contributed from both the interior and the exterior of the molecule.
As observed in other subgroup I aminotransferases, the functional unit of hKAT-I consists of a homodimer with subunits related by a dyad axis, with its two active sites located at the domain interface in each subunit, and at the subunit interface in the dimer (Fig. 3). Helices H2 and H13 participate in dimer stabilization as they are located around the 2-fold axis. Moreover, a relevant contribution toward the stability of the hKAT-I dimer is provided by its N-terminal arms. Mutational analysis carried out on pig cytosolic aspartate aminotransferase demonstrated that the integrity of the N-terminal region is of crucial importance for the enzymatic activity (42). In our crystallographic dimer, two strong salt bridges are established between Arg 8 and Asp 113 (at a dis-tance of 3.5 Å) and between Arg 9 and Glu 114 (at a distance of 3.1 Å) of the opposite subunits; such interactions, while providing a major contribution to the dimer stability, lock the N-terminal arms in the observed conformation.
The PLP Binding Site-The active site contains one PLP molecule covalently linked to Lys 247 and is hosted in a deep cleft at the domain interface built up by residues from both subunits (Fig. 3). Each PLP cofactor sits in a binding pocket defined by two regions contributed by residues of the large domains of both subunits (Fig. 4). The bottom of the PLP binding pocket is entirely defined by residues of the large domain of the corresponding monomer. With the exception of Lys 247 and Gly 100 , all of these residues stand at or close to the edge of the inner core ␤-sheet, pointing toward the domain interface and facing the re-face of the PLP-ring. Distinct arrays of residues form the lateral walls of the PLP binding pocket. In particular, the stretch 34 -37, together with the side chains of Arg 398 , Asn 181 , and Asn 185 of the large domain, builds up one of the pocket walls. The opposite wall consists of residues Tyr 101 and Tyr 128 of the same monomer and of residues Phe 278 *, His 279 * and Tyr 63 * of the other subunit. As a consequence, the PLP-pyridine ring can be seen as laterally clamped by a set of hydrophilic residues on one side and by numerous aromatic residues on the other one (Fig. 4).
In its PLP form, hKAT-I carries the PLP molecule covalently bound in the active site by a Schiff-base linkage to the catalytic Lys 247 (Fig. 4A). This results in the presence of an internal aldimine double bond (C4ЈϭN) whose plane forms an angle of 123.0°with the pyridine ring of PLP. Several other residues contact the PLP molecule, participating in its recognition and binding. The phosphate group of the cofactor is engaged in a number of interactions with residues building up the strictly conserved "PLP-phosphate binding cup" featuring PLPdependent enzymes (43). In particular, its OP1 oxygen makes a set of hydrogen bonds with Ser 244 (2.6 Å), Gly 100 (with its backbone nitrogen atom at 2.8 Å), and with the solvent molecule W7 (3.1 Å). The hydroxyl group of Tyr 63 * makes a hydrogen bond with the PLP OP2 atom (distance of 2.5 Å). A further hydrogen bond involves W34 located at 2.67 Å. Finally, the PLP OP3 atom makes interactions with Lys 255 (at 2.7 Å from the NZ atom) and with the backbone nitrogen atoms of Gly 100 and Tyr 101 (distances of 3.2 Å and 2.9 Å, respectively). The PLP phenolic oxygen is held in place by its interactions with Tyr 216 (at 2.7 Å from its OH atom) and with Asn 185 (at a distance of 2.8 Å with its NH1 atom). Moreover, the N1 atom of the PLP pyridine moiety forms hydrogen bonds with the carboxylic oxygen atoms of Asp 213 . Several hydrophobic interactions participate in the further stabilization of PLP. In particular Phe 125 and Val 215 sandwich the pyridine moiety of the cofactor from its si-face and re-face, respectively.
Substrate Recognition and Implications for Catalysis-We have been unable to produce crystals of the hKAT-I in complex with the physiological substrate L-Kyn. Attempts at obtaining the structure of hKAT-I⅐L-Kyn complex invariably yielded crystals of the PMP form (Fig. 4B), emphasizing that our crystal form is catalytically competent. However, to describe the ligand binding site in hKAT-I, we solved the structure of the Michaelis complex with L-phenylalanine, which has been reported to inhibit hKAT-I by behaving as a very poor substrate and competing with L-Kyn for binding to the enzyme active site (26). In the hKAT-I⅐Phe structure (Fig. 4C), L-Phe lies just above the PLP molecule on its si-face. Several residues structurally conserved throughout aminotransferases described so far define the ligand binding site and contact L-Phe. In particular, Asn 185 establishes a hydrogen bond with the ligand ␣-carboxylate moiety, which is further stabilized by Arg 398 . Such a conserved bonding scheme at the L-Phe carboxylic side results in the positioning of the substrate ␣-amino group just above the PLP C4Ј reactive center. A remarkable structural trait of the ligand binding site in hKAT-I consists of a series of aromatic residues, including Tyr 63 *, His 279 *, Phe 278 *, Tyr 101 , Phe 125 , and Trp 18 , that is reminiscent of a crown (Fig. 4A). In the hKAt-I⅐Phe structure (Fig. 4C), L-Phe is sandwiched between Phe 125 and His 279 *, in which the aromatic planes perpendicularly contact the ligand aromatic ring (distances for the closest pair of atoms being: 3.2 Å for L-Phe CE2-NE2 His 279 *, and 3.6 Å for L-Phe CE2-CZ Phe 125 ). A further aromatic contact is provided by Phe 278 * (closest distance of 3.3 Å) oriented with its aromatic ring almost perpendicular to the ligand ring. Notably, Phe 278 * is the only residue falling in the disallowed region of the Ramachandran plot in hKAT-I structures, suggesting that the observed conformation is functional to substrate recognition and catalysis. A major question in kynurenine aminotransferases catalysis concerns the different substrate specificities of the isozyme. Understanding the molecular determinants resulting in L-Kyn recognition by hKAT-I will prove to be critical for the rational design of selective inhibitors of potential medical interest. Sequence alignment of subgroup I aminotransferases from different species revealed that a tyrosine residue peculiarly features human and rodent L-kynurenine aminotransferases (Tyr 101 in hKAT-I). In hKAT-I we observed a striking conformational change affecting Tyr 101 . In fact, upon L-Phe binding, the Tyr 101 side chain moves 3.5 Å away from its initial position, making room for the incoming ligand (Fig. 5). Being displaced from the crown of aromatic residues that decorates the L-Phe binding pocket, Tyr 101 establishes a new hydrogen bond with Asn 275 * and becomes in contact with Cys 127 . Therefore, Tyr 101 appears to assume two alternative conformations: a close conformation in the PLP form and an open conformation in the liganded form of the enzyme. It has to be noted that Tyr 101 has been observed in the closed conformation also in the structure of the PMP form of the enzyme (Fig. 4B). We therefore propose that Tyr 101 , by alternating between an open and a closed conformation along the catalytic cycle, acts as a gate controlling substrate admission to the enzyme active site.
In aminotransferases subgroup I, ligand binding induces conformational changes resulting in the closure of the enzyme active site (41,44). Superimposition of the structures of hKAT-I in its PLP and phenylalanine-bound forms (Fig. 5) reveals a shift of the N-terminal ␣-helix H1 (residues Pro 17 -Glu 27 ), which moves toward the active site upon substrate binding. As a result, Trp 18 is brought into contact with the bound L-Phe, whose aromatic ring results perpendicularly oriented with respect to the Trp 18 indole ring at a closest distance of 3.9 Å. Such an interaction appears to play an important role in ligand recognition and stabilization, completing the set of aromatic residues surrounding and contacting the ligand (Fig. 4C). In the recently reported structure of T. thermophilus glutamine: phenylpyruvate aminotransferase (ttGlnAT) (45), a bacterial because our structural data clearly indicate a major role of the induced fit in ligand recognition, the description of the precise mode of binding of the substrate L-Kyn must await for the determination of the crystallographic structure of the hKAT-I⅐L-Kyn complex.
Role of Glu 27 -Besides of its role as excitatory amino acids antagonist, in rodents KA is also involved in the control of the cardiovascular function by acting at rostral ventrolateral medulla of the central nervous system (47,48). Spontaneously hypertensive rats, the most widely used animal model for studying genetic hypertension, have higher arterial blood pressure with respect to the normotensive Wistar Kyoto control rats. This defect has been associated with abnormally low KA levels in the central nervous system-specific districts tuning physiological blood pressure (49,50). Sequencing analysis revealed the presence of a single point mutation in the KAT-I gene in all of the examined spontaneously hypertensive rats, leading to the substitution of a glutamate by a glycine at position 61 in the enzyme (51). Remarkably, the resulting mutated protein showed a severely reduced enzymatic activity, hinting at the key role of position 61 in catalysis (51). Sequence alignment of hKAT-I and rat KAT revealed the strict conservation of a glutamic residue in this position (Glu 27 in hKAT-I).
As described above, the conformational change affecting the helix H1 upon ligand binding is a key event in the catalysis. In hKAT-I, Glu 27 represents the C terminus of the helix H1 and appears as a pivotal residue in fixing the helix in the observed conformations. In fact, it makes a strong salt bridge with Lys 23 (distance of 3.5 Å), located in the center of the helix and a weaker interaction with His 28 (distance of 5.0 Å) located in the loop following the helix H1 (Fig. 6). Based on our structural data, we propose that the substitution Glu 61 3 Gly observed in spontaneously hypertensive rats KAT (Glu 61 being equivalent to Glu 27 in hKAT-I) would affect the conformational change induced by substrate binding with dramatic consequences for the catalysis.
Conclusion-On the basis of our data, we propose that the observed conformational changes that occur in hKAT-I on ligand binding play a key role in catalysis. The shift of the ␣-helix H1 and the consequent recruitment of Trp 18 to the active site, together with the displacement of Tyr 101 (Fig. 6), result in a remodeling of the aromatic crown representing a major determinant for substrate binding. Whereas Trp 18 appears to play a relevant role in substrate specificity, Tyr 101 , by alternating between its two conformations, controls substrate admission. Such structural information will provide a solid foundation for the rational design of small molecule inhibitors specifically targeting the hKAT-I isozyme, which will prove useful both as a tool for further investigation of the biological functions of KATs and as compounds of potential medical interest. FIG. 6. Ribbon representation of the hKAT-I subunit underlining the proposed structural role of Glu 27 located at the C terminus of helix H1. In rat kynurenine aminotransferase, the indicated mutation (Glu 3 Gly) results in an hypertensive phenotype. PLP molecule and amino acid residues are drawn as a ball-and-stick representation. The N-terminal arm and the helix H1 are colored in green.